First experience with filgotinib in the upper line of treatment in patients with ulcerative colitis
Milan Lukáš1, Dana Ďuricová1
+ Affiliation
To read this article in full, please register for free on this website.
Benefits for subscribers
Benefits for logged users
Literature
1. Lukáš M. Biologická a inovativní terapie. In: Lukáš M. Pokroky v diagnostice a léčbě idiopatických střevních zánětů. Praha: Galén 2019.
2. D’Amico F, Magro F, Peyrin-Biroulet L et al. Positioning filgotinib in the treatment algorithm of moderate to severe ulcerative colitis. J Crohn’s Colitis 2022; 16(5): 835–844. doi: 10.1093/ecco-jcc/jjab206.
3. Feagan B, Danese S, Loftus EV et al. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3double – blind, randomized controlled study. Lancet 2021; 397(10292): 2372–2384. doi: 10.1016/S0140-6736(21)00666-8.
4. Schregel I, Ramos GP, Ioannou S et al. Evaluation of tofacitinib in primary sclerosing cholangitis and associated colitis: A multicenter, retrospective study. Clin Gastro Hepatol 2023; 21(12): 3448–3450. doi: 10.1016/j.cgh.2023.01.014.